Legionella Testing Market to Reach USD 455.99 Million by 2027, Rising Adoption Rapid Testing Methods to Aid in Expansion of Market

The global legionella testing market size is anticipated to reach USD 455.99 million by 2027, on account of the rising cases of legionnaire infection, pneumonia, and pontiac fever. In addition to this, the increasing number of geriatric and smoker population is also adding a boost to the market. A recently published report by Fortune Business Insights titled, “Legionella Testing Market Size, Share & Industry Analysis, By Type (Culture Media, Urine Antigen Testing (UAT), Polymerase Chain Reaction (PCR), Serology, and Direct Fluorescent Antibody (DFA) test; By End User (Hospitals & Clinics, Diagnostic Centers, and Others) and Regional Forecast, 2020-2027,” predicts the market to rise from USD 226.24 million in 2019 to reach USD 455.99 million by 2027 with a CAGR of 9.1% during the forecast period set between 2020 to 2027.

Ribotest Launches a New Series called Ribotest™ Legionella in Japan

A new product called Ribotest™ Legionella by Ribotest™ series was launched in Japan by Asahi Kasei Pharma on February 1, 2019. This new antibody technology product is developed by using the L7/L 12 protein of the bacterium. Other test kits available in the market are capable of rapidly detect 1 serogroup of Legionella pneumophilia whereas the Ribotest™ test kit can recognize at least 15 of them, thereby making it more effective and gaining popularity in the market.

This new kit is anticipated to majorly contribute to the rapid recognition and diagnosis, thereby attracting high revenue to the overall market on the one side and gaining popularity on the other. Such initiatives taken by companies are anticipated to augment the overall growth of the market in the future.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/legionella-testing-market-102803

Increasing Prevalence of Legionnaire Infections to Add Impetus to Market

The rising prevalence of hospital-acquired legionnaire diseases is a major legionella testing market growth driver. This, coupled with the rise in cases of respiratory infections among the geriatric population may augment the market during the forecast duration. Additionally, the advent of the latest testing methods such as UAT (urine antigen testing), serology, and others and their increasing popularity may also propel the growth of the market in the coming years.

On the contrary, lack of awareness about this disease, and the lack of proper medical facilities in under-developed nations may pose a major challenge to the market in terms of revenue generation.

Nevertheless, the current pandemic of COVID19 and the increasing hygiene norms followed by people all over the globe may increase the sales of legionella testing kits, thereby promoting growth. This, coupled with the strict government impositions on water testing may create lucrative growth opportunities for the market in the coming years.

Companies Investing in Collabprations to Gain Competitive Edge in Market

The competitive landscape of the global legionella testing market is consolidated in nature on account of the presence of a handful of players. They are opting for joint ventures, mergers and acquisitions, contracts and agreements, partnerships, and related strategies to gain momentum in the market competition. This, coupled with the investments for product expansion is likely to help players earn significant revenue in the coming years.

Key Industry Developments of Market include:

• August 2018 – An Ecolab Company called Nalco Water introduced a test based on molecules for legionella that can produce results at a speed of fourteen times faster than the traditional testing procedures.

List of Key Players of this Market are:

• Abbott (Alere)


• Quidel Corporation


• Bio-Rad Laboratories, Inc.


• Merck KGaA


• BD


• Thermo Fisher Scientific Inc.


• IDEXX Corporation


• bioMérieux


• Other Vendors

Further Report Findings

• North America held the dominant market share for legionella testing owing to the presence of world-class healthcare industry. This is closely followed by Europe on account of the increasing prevalence of legionella outbreak and high adoption of expensive PCR test in the region.


• With respect to segmentation by type, the market is dominated by Urine Antigen Testing (UAT0 segment with 42.2% share in the market in 2019. This is attributed to its quick results features further expected to increase its popularity in coming years.

The Market is segmented into: